With the Chinese government showing few signs of lifting stringent restrictions on international travel, the country’s drug makers are increasingly bearing the brunt of overseas approval delays due to the requirement to receive on-site facility inspections from foreign regulators including the US Food and Drug Administration.
The newest entrant to this growing list might be BeiGene, Ltd